Emcure Pharmaceuticals gains after exclusive partnership with Novo Nordisk for weight-loss drug
Emcure Pharmaceuticals’ stock rose over 8% after it entered an exclusive partnership with Novo Nordisk India to distribute and commercialise Poviztra, a semaglutide-based anti-obesity injection. The agreement positions Emcure as the first Indian company to handle the therapy locally, expanding its footprint in the obesity management market.
By Finblage Editorial Desk
2:10 pm
10 November 2025
Sources & Disclaimer
This article is compiled from publicly available information, including company disclosures, stock exchange filings, regulatory announcements, and reports from global and domestic financial publications. The content has been editorially reviewed and enhanced by the Finblage Editorial Desk for clarity and investor awareness purposes only.
All information provided on Finblage is strictly for educational and informational use and should not be considered as financial, investment, legal, or professional advice. Readers are advised to conduct their own independent research and consult a certified financial advisor before making any investment decisions. Finblage shall not be held responsible for any losses arising from the use of information published on this website.
_edited.png)





